Survodutide

What it is

Survodutide is an investigational once-weekly peptide drug candidate that activates both the glucagon receptor and the GLP-1 receptor^{[1 –5 ]}. It is part of the broader metabolic-drug development wave that includes single GLP-1 receptor agonists, dual incretin agonists, amylin combinations, and triple agonists.

Chemical structure

Survodutide, also known as BI 456906, is a synthetic peptide with molecular formula C192H289N47O61 and molecular weight of approximately 4232 g/mol^{[1 ]}. It is designed as a dual glucagon receptor and GLP-1 receptor agonist and is being developed by Boehringer Ingelheim under license from Zealand Pharma^{[1 –2 ]}.

Mechanism — different from semaglutide and tirzepatide

The dual-receptor rationale is different from semaglutide or tirzepatide. GLP-1 receptor agonism is associated with appetite reduction, glucose-dependent insulin effects, and gastrointestinal effects. Glucagon receptor agonism may increase energy expenditure and affect hepatic lipid metabolism, but it can also influence glucose biology^{[3 –6 ]}. Survodutide development is testing whether the combined receptor profile can improve obesity and liver-disease outcomes while maintaining acceptable safety and tolerability.

Indications under investigation

Survodutide is being studied for obesity, overweight with cardiometabolic risk, MASH, MASH-related fibrosis, compensated MASH cirrhosis, and cardiovascular outcomes^{[2 –8 ]}. Boehringer Ingelheim’s April 2026 topline release describes survodutide as investigational and states that it has not been approved for use and that efficacy and safety have not been established^{[2 ]}.

When used in clinical trials, survodutide is administered by subcutaneous injection^{[3 –8 ]}. These details describe clinical-trial protocols, not approved dosing guidance. There is no FDA-approved survodutide product, dose, label, indication, contraindication profile, or routine prescribing pathway^{[2 ]}.

Regulatory status

Survodutide is not FDA-approved for any indication in the United States. Boehringer Ingelheim’s April 2026 phase 3 topline release states that survodutide is an investigational agent, has not been approved for use, and that its efficacy and safety have not been established^{[2 ]}.

No approved label, no compounding pathway

No FDA-approved prescribing information for survodutide was identified in FDA approval resources reviewed for this draft. Clinical trial registration, phase 2 publication, and phase 3 topline results do not equal FDA approval.

Survodutide was not identified on the FDA 503A or 503B bulks lists reviewed for this draft^{[9 –10 ]}. Under FDA’s compounding framework, bulk drug substances used in 503A or 503B compounding must satisfy specific statutory requirements, and unapproved investigational substances should not be treated as routinely compoundable merely because they are discussed in clinical trials^{[9 –10 ]}.

Note: unlike cagrilintide and retatrutide — for which FDA explicitly states they “cannot be used in compounding under federal law” — this draft did not locate an FDA page naming survodutide directly. The conservative editorial position is the same: an investigational substance with no approved label and no bulks-list presence is not a lawful compounding target.

Controlled-substance and international status

Survodutide was not identified in the federal controlled-substance schedules in 21 CFR Part 1308 as reviewed for this draft^{[11 ]}. The central regulatory issue is FDA drug approval and investigational status, not DEA scheduling.

Internationally, no major regulatory approval was confirmed for this draft. Boehringer Ingelheim and Zealand Pharma are pursuing global phase 3 programs in obesity and MASH, including SYNCHRONIZE and LIVERAGE studies^{[2 ,7 –8 ]}.

Date of last regulatory verification: May 6, 2026.

Research summary

Phase 2 obesity dose-finding

The main published obesity efficacy study is a randomized, double-blind, placebo-controlled, dose-finding phase 2 trial of survodutide in adults with BMI at least 27 kg/m² without diabetes^{[3 ]}. Le Roux and colleagues enrolled 387 participants and studied once-weekly subcutaneous survodutide across 0.6, 2.4, 3.6, and 4.8 mg groups or placebo for 46 weeks, including a 20-week dose-escalation period and 26-week maintenance period^{[3 ,6 ]}. The published report described dose-related weight reduction; a later subgroup analysis reported that females had greater reductions in body weight and waist circumference than males and that proportional weight reduction varied by baseline BMI^{[6 ]}.

SYNCHRONIZE-1 phase 3 topline

Survodutide’s obesity phase 3 program has moved beyond design into topline results. SYNCHRONIZE-1 enrolled adults with overweight or obesity without type 2 diabetes^{[2 ]}. In April 2026, Boehringer Ingelheim reported that survodutide met its co-primary endpoints and produced mean weight loss up to 16.6% at 76 weeks using the efficacy estimand, compared with 3.2% with placebo^{[2 ]}. These results were company-reported topline data, with full data expected at ADA 2026; they should be treated as preliminary until peer-reviewed publication^{[2 ]}.

Cardiovascular outcomes — under investigation

Cardiovascular outcomes remain under investigation. Kosiborod and colleagues published the rationale and design for SYNCHRONIZE-CVOT, an event-driven cardiovascular safety study in adults with BMI at least 27 kg/m² and established cardiovascular disease, chronic kidney disease, or multiple risk factors^{[7 ]}. The target recruitment was 4,935 participants, and the primary endpoint was time to first occurrence of a composite adjudicated five-point major adverse cardiovascular event^{[7 ]}. This trial had not produced outcome results for this draft.

MASH phase 2

MASH is a major development area. Sanyal and colleagues published a 48-week phase 2 randomized trial in adults with biopsy-confirmed MASH and fibrosis stage F1 through F3^{[4 ]}. Improvement in MASH without worsening of fibrosis occurred in 47% of participants in the 2.4 mg group, 62% in the 4.8 mg group, and 43% in the 6.0 mg group, compared with 14% with placebo^{[4 ]}. Improvement in fibrosis by at least one stage occurred in 34%, 36%, 34%, and 22%, respectively^{[4 ]}. Gastrointestinal adverse events were more frequent with survodutide than placebo, including nausea, diarrhea, and vomiting^{[4 ]}.

Cirrhosis pharmacokinetics

Survodutide has also been studied in cirrhosis. Lawitz and colleagues evaluated efficacy, tolerability, and pharmacokinetics in adults with compensated cirrhosis in a trial published in Journal of Hepatology in 2024^{[5 ]}. Cirrhosis research is clinically important because hepatic impairment may affect pharmacokinetics and safety, but it does not establish broad approval for MASH cirrhosis.

Where the evidence ends

Overall, survodutide has peer-reviewed phase 2 obesity and MASH data and company-reported phase 3 obesity topline data. It remains investigational. The main unresolved questions include long-term cardiovascular outcomes, durability, comparative effectiveness versus approved obesity medications, safety in liver disease and renal disease, tolerability during dose escalation, and whether MASH histology findings translate into long-term clinical benefit.

Public discourse

Boehringer Ingelheim reported positive phase 3 obesity results while preserving investigational-status language^{[2 ]}.

Shashank Deshpande, chairman of the board of managing directors at Boehringer Ingelheim, framed survodutide as a metabolic-health candidate rather than only a weight-loss drug^{[12 ]}.

Carel W. le Roux, MBChB, PhD, obesity researcher, discussed the mechanistic rationale for glucagon and GLP-1 receptor agonism^{[13 ]}.

Arun J. Sanyal, MD, hepatologist and MASH trial investigator, framed the rationale for dual agonism in MASH^{[4 ]}.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

Survodutide has no FDA-approved prescribing information. There is no FDA-reviewed label establishing contraindications, common adverse reactions, drug interactions, pregnancy or lactation safety, long-term monitoring, or patient-selection criteria^{[2 ]}.

Gastrointestinal events

Gastrointestinal adverse events are the most prominent clinical-trial signal. In the MASH phase 2 trial, adverse events more frequent with survodutide than placebo included nausea, diarrhea, and vomiting; serious adverse events occurred in 8% of survodutide-treated participants and 7% of placebo-treated participants^{[4 ]}. The April 2026 phase 3 topline release likewise described gastrointestinal events, with discontinuations more frequent during dose escalation^{[2 ]}.

Glucagon-receptor specific concerns

The glucagon receptor component creates specific monitoring questions. Because glucagon biology affects hepatic glucose production and energy metabolism, long-term effects on glucose, liver fat, lean mass, heart rate, gallbladder disease, pancreatitis risk, and cardiovascular outcomes require careful trial interpretation^{[3 –7 ]}.

Liver disease — key population

People with liver disease are central to the development program but also a safety-sensitive population. Survodutide has been studied in MASH and cirrhosis contexts^{[4 –5 ]}, but no FDA-approved label existed as of this draft to define use in compensated or decompensated liver disease.

Gray-market product risks

Gray-market products marketed as survodutide raise separate risks, including uncertain identity, sterility, concentration, purity, stability, and dosing. Trial findings should not be generalized to research-chemical or nonclinical products.

Available through

Survodutide is not currently available through FDA-compliant prescription channels in the United States. It is investigational and has not been approved for use^{[2 ]}.

ProPeptideGuide does not link to or endorse grey-market vendors, research-chemical sellers, online peptide shops, compounded survodutide, imported products, or clinics advertising nonapproved survodutide access for weight loss, MASH, cardiometabolic risk, or performance.